NCT05825820 Pilot Study of Health System/Community Partnership for Enhanced Outreach to Prevent Suicide Attempts
| NCT ID | NCT05825820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-07-31 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-07-31 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to test an enhanced outreach intervention (EOI) delivered by Samaritans of Boston (a community organization that provides support during mental health crises) for people after they leave an emergency department (ED) visit for suicidal thoughts. The main questions the trial aims to answer are: * Is the EOI feasible and acceptable? * Can the EOI be delivered with fidelity by Samaritans staff? Participants will: * Receive outreach (by call or text) once per week for 12 weeks after ED visit. During these conversations, Samaritans staff will ask participants questions about their suicidal thoughts and behaviors, develop and review a list of coping skills to use if they have suicidal thoughts, and discuss plans for receiving mental health care. * Receive caring messages from Samaritans staff at least once per week. * Be asked to complete monthly self-report questionnaires, and participate in a phone interview with study staff at the end of the study.
Eligibility Criteria
Inclusion Criteria: 1. Currently a patient being treated and evaluated by psychiatry service in an MGB ED 2. Participants enrolled in another study (NCT05671133; PI Nock) conducted by the research team who fall into the top 50% of risk based on the suicide risk prediction algorithm used in that study 3. Able to read English 4. Ownership of a smartphone (iOS or Android) and consistent access to their smartphone following discharge from the current treatment unit or program; ability to be reliably contacted 5. Willing to provide contact information for collateral contact 6. Willing to share contact information and key clinical information with Samaritans of Boston 7. Consent to unencrypted text or email communications 8. Willing to provide social security number (SSN) or individual taxpayer identification number (ITIN) for study compensation Exclusion Criteria: 1. Any factor that impairs an individual's ability to comprehend and effectively participate in informed consent, including the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, or acute intoxication 2. Presence of extremely agitated or violent behavior at the time of consent or enrollment
Contact & Investigator
Jordan Smoller, MD, ScD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT05825820 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05825820 currently recruiting?
Yes, NCT05825820 is actively recruiting participants. Contact the research team at RFORTGANG@mgh.harvard.edu for enrollment information.
Where is the NCT05825820 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05825820 clinical trial?
NCT05825820 is sponsored by Massachusetts General Hospital. The principal investigator is Jordan Smoller, MD, ScD at Massachusetts General Hospital. The trial plans to enroll 20 participants.